142 related articles for article (PubMed ID: 36609197)
1. TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients.
Borelli B; Crucitta S; Boccaccino A; Antista M; Antoniotti C; Marmorino F; Rossini D; Conca V; Germani MM; Provenzano L; Spagnoletti A; Leone AG; Cucchiara F; Pietrantonio F; Del Re M; Danesi R; Masi G; Cremolini C; Moretto R
Tumori; 2023 Oct; 109(5):481-489. PubMed ID: 36609197
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Koper A; Wileński S; Śledzińska P; Bebyn M; Koper K
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10867-10877. PubMed ID: 37318592
[TBL] [Abstract][Full Text] [Related]
3. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
4. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
[TBL] [Abstract][Full Text] [Related]
5. The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
Marques D; Costa AL; Mansinho A; Quintela A; Pratas E; Brito-da-Silva J; Cruz J; Félix J; Rodrigues J; Mota M; Teixeira AR; Dâmaso S; Pinheiro S; Andreozzi V; Costa L; Barros AG
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):665-672. PubMed ID: 37487914
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
Bullement A; Underhill S; Fougeray R; Hatswell AJ
Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
[TBL] [Abstract][Full Text] [Related]
7. Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
Antoniotti C; Marmorino F; Boccaccino A; Martini S; Antista M; Rossini D; Zuco V; Prisciandaro M; Conca V; Zucchelli G; Borelli B; Cosentino P; Germani MM; Bosco MF; Carullo M; Vetere G; Moretto R; Giordano M; Masi G; Pietrantonio F; Zaffaroni N; Cremolini C
Eur J Cancer; 2022 Apr; 165():116-124. PubMed ID: 35231767
[TBL] [Abstract][Full Text] [Related]
8. Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.
Victorino APOS; Meton F; Mardegan L; Festa J; Piranda DN; Araujo KB
J Geriatr Oncol; 2023 May; 14(4):101477. PubMed ID: 36990929
[TBL] [Abstract][Full Text] [Related]
9. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
[TBL] [Abstract][Full Text] [Related]
10. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
[TBL] [Abstract][Full Text] [Related]
11. Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
Iveson T; Carter AM; Shiu KK; Spooner C; Stevens D; Mullamitha S
BMC Cancer; 2020 Feb; 20(1):91. PubMed ID: 32013902
[TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
13. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
[TBL] [Abstract][Full Text] [Related]
14. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
[TBL] [Abstract][Full Text] [Related]
15. Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia.
Price T; Burge M; Chantrill L; Gibbs P; Pavlakis N; Shapiro J; Sjoquist K
Asia Pac J Clin Oncol; 2020 Apr; 16 Suppl 1():3-12. PubMed ID: 32348018
[TBL] [Abstract][Full Text] [Related]
16. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
Voutsadakis IA
Curr Oncol; 2023 May; 30(6):5227-5239. PubMed ID: 37366880
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
[TBL] [Abstract][Full Text] [Related]
20. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Cremolini C; Rossini D; Martinelli E; Pietrantonio F; Lonardi S; Noventa S; Tamburini E; Frassineti GL; Mosconi S; Nichetti F; Murgioni S; Troiani T; Borelli B; Zucchelli G; Dal Maso A; Sforza V; Masi G; Antoniotti C; Di Bartolomeo M; Miceli R; Ciardiello F; Falcone A
Oncologist; 2018 Oct; 23(10):1178-1187. PubMed ID: 29739893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
